467 related articles for article (PubMed ID: 25510418)
41. Systemic Gene Delivery by Single-Dose Intracardiac Administration of scAAV2/9 and scAAV2/rh10 Variants in Newborn Rats.
Chansel-Debordeaux L; Bourdenx M; Dutheil N; Dovero S; Canron MH; Jimenez C; Bezard E; Dehay B
Hum Gene Ther Methods; 2018 Aug; 29(4):189-199. PubMed ID: 30064266
[TBL] [Abstract][Full Text] [Related]
42. Crossing the blood-brain barrier with AAV vectors.
Liu D; Zhu M; Zhang Y; Diao Y
Metab Brain Dis; 2021 Jan; 36(1):45-52. PubMed ID: 33201426
[TBL] [Abstract][Full Text] [Related]
43. Therapy for the mucopolysaccharidoses.
Valayannopoulos V; Wijburg FA
Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
[TBL] [Abstract][Full Text] [Related]
44. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.
Saraiva J; Nobre RJ; Pereira de Almeida L
J Control Release; 2016 Nov; 241():94-109. PubMed ID: 27637390
[TBL] [Abstract][Full Text] [Related]
45. Adeno-associated virus vectors and neurological gene therapy.
Ojala DS; Amara DP; Schaffer DV
Neuroscientist; 2015 Feb; 21(1):84-98. PubMed ID: 24557878
[TBL] [Abstract][Full Text] [Related]
46. Current and Emerging Therapies for Mucopolysaccharidoses.
Lagler FB
Handb Exp Pharmacol; 2020; 261():39-56. PubMed ID: 31451968
[TBL] [Abstract][Full Text] [Related]
47. Adeno-Associated Virus Vector for Central Nervous System Gene Therapy.
Zhu D; Schieferecke AJ; Lopez PA; Schaffer DV
Trends Mol Med; 2021 Jun; 27(6):524-537. PubMed ID: 33895085
[TBL] [Abstract][Full Text] [Related]
48. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
Shapiro EG; Jones SA; Escolar ML
Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
[TBL] [Abstract][Full Text] [Related]
49. Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses.
Safary A; Moghaddas-Sani H; Akbarzadeh-Khiavi M; Khabbazzi A; Rafi MA; Omidi Y
Expert Opin Biol Ther; 2021 Sep; 21(9):1181-1197. PubMed ID: 33653197
[TBL] [Abstract][Full Text] [Related]
50. Update in the Mucopolysaccharidoses.
McBride KL; Flanigan KM
Semin Pediatr Neurol; 2021 Apr; 37():100874. PubMed ID: 33892850
[TBL] [Abstract][Full Text] [Related]
51. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.
Hinderer C; Bell P; Gurda BL; Wang Q; Louboutin JP; Zhu Y; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Haskins ME; Wilson JM
Mol Ther; 2014 Dec; 22(12):2018-2027. PubMed ID: 25027660
[TBL] [Abstract][Full Text] [Related]
52. The advent of AAV9 expands applications for brain and spinal cord gene delivery.
Dayton RD; Wang DB; Klein RL
Expert Opin Biol Ther; 2012 Jun; 12(6):757-66. PubMed ID: 22519910
[TBL] [Abstract][Full Text] [Related]
53. Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.
Joshi CR; Labhasetwar V; Ghorpade A
J Neuroimmune Pharmacol; 2017 Mar; 12(1):51-83. PubMed ID: 28160121
[TBL] [Abstract][Full Text] [Related]
54. Overview of the mucopolysaccharidoses.
Muenzer J
Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v4-12. PubMed ID: 22210669
[TBL] [Abstract][Full Text] [Related]
55. The final frontier -- crossing the blood-brain barrier.
Sly WS; Vogler C
EMBO Mol Med; 2013 May; 5(5):655-7. PubMed ID: 23653302
[No Abstract] [Full Text] [Related]
56. Abnormal polyamine metabolism is unique to the neuropathic forms of MPS: potential for biomarker development and insight into pathogenesis.
Hinderer C; Katz N; Louboutin JP; Bell P; Tolar J; Orchard PJ; Lund TC; Nayal M; Weng L; Mesaros C; de Souza CFM; Dalla Corte A; Giugliani R; Wilson JM
Hum Mol Genet; 2017 Oct; 26(19):3837-3849. PubMed ID: 28934395
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.
Sawamoto K; Stapleton M; Alméciga-Díaz CJ; Espejo-Mojica AJ; Losada JC; Suarez DA; Tomatsu S
Drugs; 2019 Jul; 79(10):1103-1134. PubMed ID: 31209777
[TBL] [Abstract][Full Text] [Related]
58. [Neurologic manifestations in mucopolysaccharidoses].
Héron B
Arch Pediatr; 2014 Jun; 21 Suppl 1():S14-21. PubMed ID: 25063379
[TBL] [Abstract][Full Text] [Related]
59. Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.
Bey K; Ciron C; Dubreil L; Deniaud J; Ledevin M; Cristini J; Blouin V; Aubourg P; Colle MA
Gene Ther; 2017 May; 24(5):325-332. PubMed ID: 28425480
[TBL] [Abstract][Full Text] [Related]
60. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.
Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A
Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
